NCT00674908已完成4 期
A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 144
- 试验地点
- 6
- 主要终点
- Seroprotection rates for Diphtheria, Tetanus, Pertussis, Hepatitis B and Hib following 3 doses of the vaccines in a single and mixed sequence regimen.
研究概览
简要总结
The objective of this study is to compare the Safety and Immunogenicity of a mixed sequence of 2 different pentavalent vaccines (Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib combination Vaccines) with single sequence of Shan 5 in infants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 6 Weeks 至 8 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy children in the age group six to eight weeks
- •Born after a normal gestational period (36 - 42 weeks)
- •Mother's HBsAg assured negative.
- •Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form.
- •Parents willing to fill the Diary Card
排除标准
- •Administration of immunoglobulin or any blood products since birth.
- •Use of any investigational, on-registered drug, or vaccine other than the study vaccine (with the exception of OPV & BCG vaccine) during the study period or within 30 days preceding the first dose of the study vaccine.
- •Previous vaccination or evidence of infection with DTP or Hib.
- •History of allergic disease or reaction likely to be exacerbated by any component of the vaccine including allergy to antibiotics.
- •Major congenital or hereditary immunodeficiency.
- •Infants having evidence of disease or fever, history of allergic disease or persistent hematological, hepatic, renal, cardiac or respiratory disease and signs of a CNS disorder at the time of vaccination.
- •Infants showing any of the following reactions after any dose of study vaccine will be withdrawn for subsequent doses: body temperature more than 40.4 degree Celsius, persistent screaming or crying for 3 hours within 48 hours of vaccination, seizures, encephalopathy and hypersensitivity reaction.
- •Parent/s or guardian of subject unable to maintain diary card
- •Simultaneous participation in any other clinical study
结局指标
主要结局
Seroprotection rates for Diphtheria, Tetanus, Pertussis, Hepatitis B and Hib following 3 doses of the vaccines in a single and mixed sequence regimen.
时间窗: 4 months
次要结局
- Solicited and unsolicited local and systemic adverse events following vaccination(4 months)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUREncephalitis, Tick-borneNCT00161824Pfizer3,800
已完成
1 期
HIV Vaccine Study in HIV Positive PatientsHIV InfectionsNCT01071031PepTcell Limited54
已完成
2 期
Phase II Tularemia Vaccine ComparisonTularaemiaNCT01150695National Institute of Allergy and Infectious Diseases (NIAID)228
已完成
1 期
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's DiseaseAlzheimer DiseaseDementia AlzheimersDementia, MildNCT05328115Alzinova AB33
已完成
1 期
Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected AdultsHealthyNCT02788045Janssen Vaccines & Prevention B.V.201